In particular, ethical drugs (class A and class C) recorded +1.4% in value and confirmed the evolution in consumption (+3% per unit).
In the first two months of 2015, the pharmacy market in Italy grew by 4%, in particular ethical medicines (Class A and Class C) grew in value by 1.4% and confirmed the positive evolution in consumption (+3% in unit). These are the data released by IMS Health Italia, a world-leading company in the supply of information services and technological solutions dedicated to the pharmaceutical market, which photographed the Italian pharmacy market.
The growth of the sector is also confirmed by the data relating to self-care drugs (SOP - Without Prescription and Self-Medication) which show a very positive start to the year with +8% in volumes and +10% in values.
"This positive evolution can be partly explained by a seasonality which, in these two months of the year, has raised the demand for prescription drugs for the respiratory tract, antipyretics and antibiotics and for self-medication products for seasonal diseases - he commented Sergius Liberator, 
general manager of IMS Health Italia – However, we also recorded significant growth in more luxury commercial segments such as nutraceuticals and, above all, cosmetics. We believe this can be read as a sign of a recovery of confidence from the pharmacy customers."
Therefore, after an almost continuous series of negative signs for the ethical market during 2014, from December 2014 to February 2015 the evolution of the Italian pharmacy market recovered and saw three plus signs also in the prescription drug segment.
IMS Health is a leading global provider of information services and technology solutions dedicated to the pharmaceutical market for measuring and improving business performance. The sophisticated analysis tools and proprietary application solutions residing on the IMS One cloud infrastructure allow for the integration of more than 10 petabytes of data relating to therapeutic areas, treatments, costs and outcomes capable of guaranteeing more efficient operational management.
IMS Health operates 100,000 data sources globally and processes 45 million healthcare transactions annually. AND' leader in the protection of confidentiality and uses anonymous data to provide qualified and accurate information on therapeutic areas and related treatments. Active in Italy since 1960, with offices in Rome and Milan, today it has about 200 employees who work in the areas of data collection and processing, market research, technological consultancy and strategic marketing.
The information provided by IMS Health assists pharmaceutical companies, biotechnology companies, researchers and government agencies in identifying unmet medical needs and understanding the efficacy and value of pharmaceutical products in improving patient outcomes.
Related news: OVER THE HORIZON: IMS HEALTH REVEALS 2018 PHARMACEUTICAL NUMBERS
